Last edition
News about "diabetic retinopathy "
Lupin Receives US FDA Approval for Interchangeable Biosimilar Ranibizumab, Ranluspec
Lupin has secured US FDA approval for Ranluspec (ranibizumab-hkdz), an interchangeable biosimilar to Lucentis, expanding its biosimilars portfolio and broadening access to treatments for retinal and vision-related disorders.
Diabetic Retinopathy | 05/06/2026 | By News Bureau | 112
Bayer to Acquire Perfuse Therapeutics to Boost Ophthalmology Pipeline
Bayer to acquire Perfuse Therapeutics, strengthening its ophthalmology pipeline with a potential disease-modifying therapy for glaucoma and diabetic retinopathy.
Diabetic Retinopathy | 07/05/2026 | By News Bureau
Celltrion Receives US FDA Approval for EYLEA Biosimilar EYDENZELT
Celltrion has received approval from the US Food and Drug Administration (FDA) for EYDENZELT (aflibercept-boav), a biosimilar to EYLEA (aflibercept), for the treatment of neovascular (wet) age-related macular degeneration (wAMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), and diabetic retinopathy (DR).
Diabetic Retinopathy | 11/10/2025 | By Dineshwori | 340
Palatin Technologies, the US-based biopharmaceutical company focused on developing medicines that modulate the melanocortin receptor system, announced it has achieved a research milestone under its collaboration with Boehringer Ingelheim, triggering a 6.5 million payment to the company.
Diabetic Retinopathy | 23/09/2025 | By Dineshwori | 150
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy